The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain

Maravilla-Herrera, Paulina; Merino, María; Zamora, Santiago Alfonso; Filgueiras, Jesús Balea; Carrillo, J.M. Carrascosa; Sánchez, Olga Delgado; Sinisterra, Francisco Dolz; García-Ruiz, Antonio; Pinto, Pedro Herranz; Manfredi, Antonio; Olmos, José Martínez; Luna, Paloma Morales de los Ríos; Puig, Lluís; Ros, S.; Hidalgo-Vega, Álvaro

doi:10.3389/fpubh.2023.1000776

Cited by 3 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A PASI 75 score indicates a 75% or greater reduction in PASI score from baseline, representing significant disease improvement. This criterion has been traditionally used as a benchmark for treatment efficacy in clinical trials ( 30 , 31 ). Therefore, respondents are defined as patients who have improved PASI by ≥ 75% after 16 weeks of treatment, whereas non-responders were defined as <75% improvement in PASI.…”

Section: Methodsmentioning

confidence: 99%

IL-17A inhibitors alleviate Psoriasis with concomitant restoration of intestinal/skin microbiota homeostasis and altered microbiota function

Zhao,

Shang,

Zhang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundDisturbed gut microbiota and associated metabolic dysfunction exist in Psoriasis. Despite the growing use of interleukin-17 inhibitor (anti-IL17) therapy, the effect of anti-IL17 on gut/skin microbiota function is not fully understood in patients with Psoriasis.ObjectiveTherefore, we explored whether Psoriasis is associated with alterations in selected gut/skin microbiota in a study cohort, and a longitudinal cohort study to reveal the effects of IL-17A inhibitor treatment on gut microbiota in Psoriasis.MethodsIn a case-control study, 14 patients with Psoriasis and 10 age, sex and body mass index-matched Healthy Controls were recruited. Longitudinal mapping of the gut microbiome was performed using 16S rRNA gene sequencing. Mouse models were used to further study and validate the interrelationship between the skin microbiome and the gut microbiome in Psoriasis. PICRUST2 was applied to predict the function of the bacterial community.ResultsIn Psoriasis patients, gut microbiota dysbiosis was present with increased heterogeneity: decreased Bacteroidota and increased Firmicutes as well as Actinobacteriota predominating in Psoriasis. Escherichia-Shigella enrichment was associated with reduction in serum levels of total bile acid and markers in Apoptotic pathways. After IL-17A inhibitor treatment in Psoriasis patients, longitudinal studies observed a trend toward a normal distribution of the gut microbiome and modulation of apoptosis-related metabolic pathways. Results from a mouse model showed dysregulation of the skin microbiota in Psoriasis characterized by Staphylococcus colonization.ConclusionThe psoriatic gut/skin microbiota exhibits loss of community stability and pathogen enrichment. IL-17A inhibitors restore microbiota homeostasis and metabolic pathways, reduce pro-inflammatory cytokine expression, and alleviate symptoms in patients with Psoriasis.

show abstract

Section: Methodsmentioning

confidence: 99%

IL-17A inhibitors alleviate Psoriasis with concomitant restoration of intestinal/skin microbiota homeostasis and altered microbiota function

Zhao,

Shang,

Zhang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…PASI75 is the key measure of treatment effectiveness, with PASI90 or even PASI100 becoming sought-after with advanced therapies ( 14 ). The general questionnaire covers sociodemographics: gender, age, marital status, residency, education, property, and employment.…”

Section: Methodsmentioning

confidence: 99%

The Influence of Treatment Modalities on the Quality of Life of Psoriasis Patients

Milidrag,

Safiye,

Gutić

et al. 2023

ijph

View full text Add to dashboard Cite

Background: We aimed to identify the quality of life (QoL) of patients with psoriasis, to determine the possible differences depending on the therapeutic modalities (biologic, conventional treatment and phototherapy), and to examine other variables that could affect the success of the treatment. Methods: This research was a non-experimental, quantitative, observational study that included 183 psoriasis patients. The study was conducted from November 2021 to December 2022 at the University Clinical Center Kragujevac, Serbia. The following instruments were used: Dermatology Life Quality Index (DLQI), Psoriasis Area and Severity Index (PASI), as well as a general questionnaire that contained a set of questions which referred to sociodemographic data. Results: There was a statistically significant difference in the average values of the DLQI score concerning the application of different therapeutic modalities (P<0.001). Biologic treatment was the modality with the lowest impairments in the QoL domain (average value of DLQI score 10.6±7.3), followed by patients on conventional treatment (average value of DLQI score 12.9±7.9), and the highest levels of impaired QoL were in patients who received phototherapy (average value of the DLQI score 13.7±9.3). Conclusion: Patients on biological therapy at all four time points individually (baseline, 4, 12 and 16 weeks) had the lowest average values of the DLQI score, i.e. the best QoL compared to subjects who received other therapy.

show abstract

“…Die Autoren der zu besprechende spanischen Studie haben nun die sozialen Auswirkungen eines höheren PASI-Outcomes untersucht, um mögliche Assoziationen von therapeutischem Ergebnis und ökonomischen und sozialen Auswirkungen aufzudecken [4]. Sie haben hierzu einen 12-Monats-Horizont für die Kalkulation ökonomischer und sozialer Effekte verwendet.…”

Section: Transfer In Die Praxis Von Prof Dr Uwe Wollina (Dresden)unclassified

Psoriasis: Wie therapeutische Ergebnisse mit ökonomischen und sozialen Auswirkungen in Verbindung stehen

Wollina¹

2023

Kompass Dermatol

View full text Add to dashboard Cite

Introduction: Psoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement of at least 75% with respect to the baseline PASI score, has traditionally been used as a therapeutic benchmark in clinical trials. Therapeutic advances have made PASI 90 or PASI 100 responses possible in most patients treated with some biologics. A greater response may generate social value beyond clinical outcomes that would benefit both patients and society. Methods: A 1-year economic model was applied to estimate the impact of having a PASI 75, PASI 90, or PASI 100 response in four areas of analysis (quality of life, activities of daily living, work productivity, and out-of-pocket expenditures) and the social value of having a PASI 90 or PASI 100 response in comparison with a PASI 75 response. A mixed-methods approach based on the scientific literature, a focus group with patient, and an advisory committee with psoriasis stakeholders was used. The model included three different scenarios: having a PASI 90 vs a PASI 75 response; a PASI 100 vs a PASI 90 response; and a PASI 100 vs a PASI 75 response. A sensitivity analysis was included. Results: The annual economic impact per patient with moderate-to-severe plaque psoriasis having a PASI 75 response was estimated at Ł 6,139, mainly related to labour productivity losses and quality of life reductions. Having a PASI 90 or a PASI 100 response would reduce this impact to €3,956 or €1,353, respectively. Accordingly, the social value of having a PASI 90 instead of a PASI 75 response was estimated at €2,183, and €4,786 with a PASI 100 response. Discussion: A PASI 90 or PASI 100 response would have a lower economic impact and a greater social value than a PASI 75 response for patients with moderate-to-severe plaque psoriasis.

show abstract

The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain

Cited by 3 publications

References 32 publications

IL-17A inhibitors alleviate Psoriasis with concomitant restoration of intestinal/skin microbiota homeostasis and altered microbiota function

IL-17A inhibitors alleviate Psoriasis with concomitant restoration of intestinal/skin microbiota homeostasis and altered microbiota function

The Influence of Treatment Modalities on the Quality of Life of Psoriasis Patients

Psoriasis: Wie therapeutische Ergebnisse mit ökonomischen und sozialen Auswirkungen in Verbindung stehen

Contact Info

Product

Resources

About